Amyloid β-Peptide (1-42) (human)
Amyloid beta-Peptide (1-42) (human) (CAS 107761-42-2) is a 42-amino-acid peptide that plays a key role in the pathogenesis of Alzheimer's disease (AD) [1].
Its major deleterious effects in pathogenesis may be mediated by Aβ42, which acts as a repressor or activator of gene transcription, leading to further synaptic dysfunction and neuronal degeneration [2].
When Aβ42 concentration reaches 2.5 μM, the survival rate of SH-SY5Y cells drops to 65%. Using chromatin immunoprecipitation (ChIP) and qRT-PCR assays, treatment of SH-SY5Y cells with Aβ42 enables the peptide to bind the LRP1 and KAI1 promoters simultaneously and elevates APP mRNA levels; in contrast, the non-toxic Aβ42 G33A peptide, which is abundant in the nucleus, has no effect on mRNA expression. Compared with several peptides of different lengths, Aβ42 treatment specifically increases the transcription and expression of its precursor gene APP [1].
Aβ42 participates in regulating voltage-gated Ca2+ and K+ channel functions on the neuronal surface membrane. Applied in the perfusate at appropriate concentrations (1 to 10 μM), Aβ42 has no effect on delayed rectifier K+ currents and leak currents but enhances the inactivation of Ca2+ currents and blocks Ca2+-dependent K+ currents [3].
Amyloid beta-Peptide (1-42) is commonly used to establish Alzheimer's disease (AD) animal models, and intracerebral injection induces neuronal damage and learning and memory dysfunction.
References
[1] Barucker C, Harmeier A, Weiske J, et al. Nuclear Translocation Uncovers the Amyloid Peptide Aβ42 as a Regulator of Gene Transcription. The journal of biological chemistry, 2014, 289(29): 20182-20191.
[2] Hardy J and Selkoe D J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297(5580): 353-356.
[3] Solntseva E I, Bukanova J V, Marchenko E V, et al. Impact of Amyloid-β Peptide (1-42) on Voltage-Gated Ion Currents in Molluscan Neurons. Bulletin of experimental biology and medicine, 2011, 151(6): 671-674.
- 1. Ruyun Liu, Minzhen Wei, et al. "A Keap1-Nrf2 protein-protein interaction inhibitor 4–95 ameliorates cognitive dysfunction by suppressing neuronal ferroptosis." Bioorg Chem. 2026 Jun 17:180:110134. PMID: 42322910
- 2. Si-Hai Wu, Junjie Ma, et al. "Ratiometric Imaging Detection of Amyloid-β Fibrils by a Dual-Emissive Tris-Heteroleptic Ruthenium Complex." Inorg Chem. 2024 Sep 30;63(39):17983-17992. PMID: 39287976
- 3. Lanlan Jing, Wenxiu Wei, et al. "Rapid discovery and crystallography study of highly potent and selective butylcholinesterase inhibitors based on oxime-containing libraries and conformational restriction strategies." Bioorg Chem. 2023 May:134:106465. PMID: 36933339
- 4. Omar SH, Scott CJ, et al. "Olive Biophenols Reduces Alzheimer's Pathology in SH-SY5Y Cells and APPswe Mice." Int J Mol Sci. 2018 Dec 30;20(1).pii: E125. PMID: 30598025
- 5. Gauba E, Chen H, et al. "Cyclophilin D deficiency attenuates mitochondrial F1Fo ATP synthase dysfunction via OSCP in Alzheimer's disease." Neurobiol Dis. 2018 Sep 26;121:138-147. PMID: 30266287
| Storage | Store at -20°C |
| M.Wt | 4514.08 |
| Cas No. | 107761-42-2 |
| Formula | C203H311N55O60S |
| Synonyms | β-Amyloid (1-42), human TFA |
| Solubility | insoluble in H2O; insoluble in EtOH; ≥40.5 mg/mL in DMSO |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure

Related Biological Data

Related Biological Data
















